BR0013638A - New interferon beta-like molecules - Google Patents

New interferon beta-like molecules

Info

Publication number
BR0013638A
BR0013638A BR0013638-7A BR0013638A BR0013638A BR 0013638 A BR0013638 A BR 0013638A BR 0013638 A BR0013638 A BR 0013638A BR 0013638 A BR0013638 A BR 0013638A
Authority
BR
Brazil
Prior art keywords
interferon
amino acid
polypeptide
molecules
interferon beta
Prior art date
Application number
BR0013638-7A
Other languages
Portuguese (pt)
Inventor
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Kim Vilbour Andersen
Claus Bornaes
Poul Baad Rasmussen
Original Assignee
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Aps filed Critical Maxygen Aps
Publication of BR0013638A publication Critical patent/BR0013638A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

"NOVAS MOLéCULAS SEMELHANTES A INTERFERON BETA". Conjugado que exibe atividade de interferon <225> e que compreende pelo menos uma primeira porção não-polipeptídica ligada de modo covalente a um polipeptídeo de interferon <225>, a seq³ência de aminoácidos que difere daquela de interferon <225> humano de tipo selvagem em pelo menos um resíduo de aminoácido introduzido e pelo menos um resíduo de aminoácido removido que compreende um grupo de anexação para a referida primeira porção não-polipeptídica. A primeira porção não-polipeptídica é, por exemplo, uma molécula polimérica ou uma porção de açúcar. O conjugado encontra uso particular em terapia."NEW INTERFERON BETA SIMILAR MOLECULES". Conjugate exhibiting interferon? Activity and comprising at least a first non-polypeptide moiety covalently linked to an interferon? Polypeptide, the amino acid sequence that differs from that of wild-type human interferon? at least one introduced amino acid residue and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is, for example, a polymeric molecule or a sugar moiety. The conjugate finds particular use in therapy.

BR0013638-7A 1999-08-27 2000-08-25 New interferon beta-like molecules BR0013638A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199901197 1999-08-27
US16078299P 1999-10-21 1999-10-21
DKPA199901691 1999-11-26
DKPA200000194 2000-02-07
DKPA200000363 2000-03-07
DKPA200000642 2000-04-14
PCT/DK2000/000471 WO2001015736A2 (en) 1999-08-27 2000-08-25 Interferon-beta conjugates

Publications (1)

Publication Number Publication Date
BR0013638A true BR0013638A (en) 2002-05-14

Family

ID=27545189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013638-7A BR0013638A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules

Country Status (14)

Country Link
EP (1) EP1328295A2 (en)
JP (1) JP2003527090A (en)
KR (1) KR20020034181A (en)
CN (1) CN1501815A (en)
AU (1) AU6687000A (en)
BR (1) BR0013638A (en)
CA (1) CA2380760A1 (en)
CZ (1) CZ2002521A3 (en)
HU (1) HUP0302674A2 (en)
IL (1) IL147581A0 (en)
MX (1) MXPA02001969A (en)
NO (1) NO20020929L (en)
SK (1) SK2942002A3 (en)
WO (1) WO2001015736A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287918B6 (en) 1998-10-16 2012-03-02 Biogen Idec Ma Inc. Composition containing glycosylated interferon-beta-1a, pharmaceutical composition, use of composition, in-vitro method of prolonging the activity of interferon-beta-1a and use of polymer moiety
SK287491B6 (en) 1998-10-16 2010-11-08 Biogen Idec Ma Inc. Interferon-beta-1 fusion proteins and their use
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
IL156059A0 (en) 2001-02-27 2003-12-23 Maxygen Aps NEW INTERFERON beta-LIKE MOLECULES
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
KR100511749B1 (en) * 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
UA82184C2 (en) 2002-01-18 2008-03-25 Байоджин Айдек Ма Инк. Polyalkylene glycol with residue for conjugation of bioactive compound
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003303635B2 (en) * 2002-12-26 2009-07-23 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
EP1666496B1 (en) * 2003-08-25 2014-03-12 Toray Industries, Inc. Interferon-beta composite
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CN101506232A (en) * 2006-08-08 2009-08-12 诺瓦提斯公司 Recombinant interferon-beta with enhanced biological activity
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)
WO2016073825A1 (en) 2014-11-06 2016-05-12 Pharmaessentia Corporation Dosage regimen for pegylated interferon
EP3454887B1 (en) * 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation Composition for treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
CA2279986A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
EP1012184B1 (en) * 1997-07-14 2007-10-10 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
SK287918B6 (en) * 1998-10-16 2012-03-02 Biogen Idec Ma Inc. Composition containing glycosylated interferon-beta-1a, pharmaceutical composition, use of composition, in-vitro method of prolonging the activity of interferon-beta-1a and use of polymer moiety

Also Published As

Publication number Publication date
EP1328295A2 (en) 2003-07-23
KR20020034181A (en) 2002-05-08
JP2003527090A (en) 2003-09-16
MXPA02001969A (en) 2003-07-21
NO20020929D0 (en) 2002-02-26
CA2380760A1 (en) 2001-03-08
HUP0302674A2 (en) 2003-11-28
AU6687000A (en) 2001-03-26
WO2001015736A3 (en) 2003-05-22
IL147581A0 (en) 2002-08-14
CN1501815A (en) 2004-06-02
NO20020929L (en) 2002-04-25
SK2942002A3 (en) 2002-08-06
CZ2002521A3 (en) 2002-05-15
WO2001015736A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
BR0013638A (en) New interferon beta-like molecules
BR0015506A (en) Gamma interferon conjugates, methods for their preparation, pharmaceutical compositions that comprise the molecules and their use in the treatment of diseases
BR0207576A (en) Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
BR8906988A (en) TETRAPIPTIDIO, PEPTIDE, PHARMACEUTICAL COMPOSITION, PROCESS FOR USE OF PEPTIDE AND REAGENT FOR DIAGNOSIS
BR9808881A (en) Compounds for prostate cancer immunotherapy and methods for their use
ES2139012T3 (en) PEPTIDES OF HUMAN P53 PROTEIN INTENDED FOR USE IN COMPOSITIONS THAT INDUCE A REACTION IN HUMAN T-LYMPHOCYTES, AND SPECIFIC T-CYTOTOXIC T-LYMPHOCYTES.
BR9907189A (en) Products of the lipid fraction of the sea cucumber carotenoid and methods of use
BR9713914A (en) Compound, use of it, pharmaceutical composition, and process to treat a patient suffering from a disorder that is susceptible to treatment with a thrombopoietin agonist.
BR9909860A (en) Specific cd19xcd3 polypeptides and their uses
ATE289350T1 (en) TNF RECEPTOR, TNF BINDING PROTEINS AND DNA CODING THEREOF
BR9911305A (en) Nitrate salts, process for preparing the same, pharmaceutical compositions, and use of them
ATE389724T1 (en) HUMAN DNASE I HYPERACTIVE VARIANTS
BR9915940A (en) Methods and compositions to restore the conformational stability of a protein of the p53 family
BR9910573A (en) Antipicornoviral compounds, preparation and use thereof
BR9508467A (en) Somatostatin receptor binding peptide matter composition pharmaceutical composition and process for performing radiosotope-guided surgery or a radiodiagnostic or radiotherapeutic procedure and for alleviating a somatostetin-related disease in an animal
BR9812394A (en) Terminally truncated amino mcp-2 as chemokine antagonists
PT820303E (en) ANALYSIS OF P277 PEPTIDE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM FOR TREATMENT OR DIAGNOSIS OF DIABETES
BR9607628A (en) Biologically isolated proteinaceous molecule, recombinant molecule, peptide fragment, nucleic acid molecule, pharmaceutical composition, and processes for preparing a recombinant molecule and for inducing astroglial proliferation in a mammal
BR0206852A (en) Neublastin polymer conjugates and methods for using them
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
BR9813514A (en) Agent for the treatment of keratin fibers
FI972170A (en) Peptides capable of binding to the SH3 domain of the GAP protein, nucleotide sequences encoding these peptides, their preparation and use
BR0016419A (en) Method for increasing immunization responses with respect to herpes simplex virus vaccine
BR0014803A (en) Peptide, pharmaceutical composition, use of one or more of the peptides, and diagnostic composition
BR0207327A (en) Biotin-derived amino acids and their conjugates with macrocyclic chelating agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. A CLASSIFICACAO IPC ANTERIOR ERA A61K 47/48.

Ipc: B82Y 5/00 (2011.01), A61K 38/21 (2006.01)

Ipc: B82Y 5/00 (2011.01), A61K 38/21 (2006.01)